Wai Yuen Tong Medicine Holdings (897) Stock Overview
An investment holding company, engages in production and sale of Chinese and western pharmaceuticals and health food products in Mainland China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
897 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Wai Yuen Tong Medicine Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.40 |
| 52 Week High | HK$0.51 |
| 52 Week Low | HK$0.20 |
| Beta | -0.055 |
| 1 Month Change | -13.19% |
| 3 Month Change | 3.95% |
| 1 Year Change | 92.68% |
| 3 Year Change | 25.40% |
| 5 Year Change | -3.66% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Benign Growth For Wai Yuen Tong Medicine Holdings Limited (HKG:897) Underpins Its Share Price
Sep 03
There's No Escaping Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Muted Revenues Despite A 25% Share Price Rise
Feb 27Wai Yuen Tong Medicine Holdings Limited (HKG:897) Stock Catapults 50% Though Its Price And Business Still Lag The Industry
Jan 06Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Low P/S No Reason For Excitement
Nov 19Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too
Jul 26Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
Mar 11The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business
Dec 28Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Jul 11Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt
Jul 05Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Mar 08Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
Aug 18Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Mar 17Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
Jan 22Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Dec 16
Shareholder Returns
| 897 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 3.9% | 0.7% | -1.7% |
| 1Y | 92.7% | 67.7% | 29.4% |
Return vs Industry: 897 exceeded the Hong Kong Pharmaceuticals industry which returned 67.7% over the past year.
Return vs Market: 897 exceeded the Hong Kong Market which returned 29.4% over the past year.
Price Volatility
| 897 volatility | |
|---|---|
| 897 Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.3% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 897's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 897's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 726 | Kit Man Chan | www.wyth.net |
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, engages in production and sale of Chinese and western pharmaceuticals and health food products in Mainland China and Hong Kong. The company manufactures, processes, and sells traditional Chinese medicines under the brand Wai Yuen Tong brand and western pharmaceutical and personal care products under the Madame Pearl’s and Pearl’s brands. It also invests in commercial premises for rental.
Wai Yuen Tong Medicine Holdings Limited Fundamentals Summary
| 897 fundamental statistics | |
|---|---|
| Market cap | HK$444.42m |
| Earnings (TTM) | -HK$13.83m |
| Revenue (TTM) | HK$721.27m |
Is 897 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 897 income statement (TTM) | |
|---|---|
| Revenue | HK$721.27m |
| Cost of Revenue | HK$361.54m |
| Gross Profit | HK$359.73m |
| Other Expenses | HK$373.56m |
| Earnings | -HK$13.83m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 49.87% |
| Net Profit Margin | -1.92% |
| Debt/Equity Ratio | 25.5% |
How did 897 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 02:07 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wai Yuen Tong Medicine Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.